

Natalie Cook

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8428856/natalie-cook-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

3,972
citations

22
h-index

46
g-index

46
ext. papers

4,588
ext. citations

9.2
avg, IF

4.9
L-index

#	Paper	IF	Citations
43	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021 , 27, 793-801	50.5	18
42	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 124, 391-398	8.7	2
41	Integration of early supportive and palliative care in a patient's journey with cancer. <i>Progress in Palliative Care</i> , 2019 , 27, 206-212	1	
40	Challenge of the Unknown: How Can We Improve Clinical Outcomes in Cancer of Unknown Primary?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2089-2090	2.2	4
39	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. <i>Nature Medicine</i> , 2019 , 25, 738-743	50.5	119
38	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'. <i>British Journal of Cancer</i> , 2019 , 120, 141-153	8.7	45
37	How to Design Phase I Trials in Oncology 2018 , 165-187		
36	A phase I trial of the ßsecretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2018 , 118, 793-801	8.7	55
35	Drug development and clinical trial design in pancreatico-biliary malignancies. <i>Current Problems in Cancer</i> , 2018 , 42, 73-94	2.3	4
34	Exome-Wide Association Study of Pancreatic Cancer Risk. <i>Gastroenterology</i> , 2018 , 154, 719-722.e3	13.3	27
33	Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. <i>Npj Genomic Medicine</i> , 2018 , 3, 15	6.2	8
32	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017 , 123, 1409-1415	4.15	4
31	Reply to K.K. Sahu et al. <i>Journal of Oncology Practice</i> , 2017 , 13, 215	3.1	
30	Novel Early Phase Clinical Trial Design in Oncology. <i>Pharmaceutical Medicine</i> , 2017 , 31, 297-307	2.3	2
29	E-Mail Communication Practices and Preferences Among Patients and Providers in a Large Comprehensive Cancer Center. <i>Journal of Oncology Practice</i> , 2016 , 12, 676-84	3.1	11
28	Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. <i>British Journal of Cancer</i> , 2016 , 114, 381-7	8.7	47
27	TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS11614-TPS11614	2.2	5

26	FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. <i>British Journal of Cancer</i> , 2016 , 115, 649-54	8.7	35
25	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , 2015 , 9, 997-1007	7.9	59
24	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , 2015 , 20, 653-9	5.7	18
23	Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2015 , 68, 309-13	3.9	16
22	Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. <i>Ecological Management and Restoration</i> , 2015 , 28, 612-8	3	16
21	FOLFIRINOX for advanced pancreatic cancer: The Princess Margaret experience.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 417-417	2.2	1
20	Email communication practices and preferences among patients and providers in a large comprehensive cancer center.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6519-6519	2.2	
19	Developing a Cancer genomics Digital Educational Tool to assess the knowledge and expectations of patients with advanced solid tumors (CADET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6524-6524	2.2	
18	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2014 , 15, 78-86	21.7	413
17	Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. <i>British Journal of Cancer</i> , 2014 , 111, 318-25	8.7	16
16	Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. <i>Gut</i> , 2013 , 62, 112-20	19.2	690
15	Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. <i>PLoS ONE</i> , 2013 , 8, e67330	3.7	24
14	Predictive in vivo animal models and translation to clinical trials. <i>Drug Discovery Today</i> , 2012 , 17, 253-60	8.8	80
13	Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. <i>Pancreatology</i> , 2012 , 12, 8-15	3.8	46
12	A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer. <i>Statistics in Medicine</i> , 2012 , 31, 1931-43	2.3	12
11	nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. <i>Cancer Discovery</i> , 2012 , 2, 260-269	24.4	309
10	Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. <i>Journal of Experimental Medicine</i> , 2012 , 209, 437-44	16.6	78
9	The pancreas cancer microenvironment. <i>Clinical Cancer Research</i> , 2012 , 18, 4266-76	12.9	863

8	Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. <i>Gut</i> , 2012 , 61, 877-84	4.2	54
7	Stromal biology and therapy in pancreatic cancer. <i>Gut</i> , 2011 , 60, 861-8	19.2	532
6	A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1243-53	3.5	42
5	The International Core Literature Consensus (ICLC): an alternative curriculum for Oncologists. <i>Journal of Cancer Education</i> , 2011 , 26, 420-6	1.8	3
4	Crosstalk between the canonical NF- κ B and Notch signaling pathways inhibits Ppar α expression and promotes pancreatic cancer progression in mice. <i>Journal of Clinical Investigation</i> , 2011 , 121, 4685-99	15.9	184
3	A phase 2 study of vatalanib in metastatic melanoma patients. <i>European Journal of Cancer</i> , 2010 , 46, 2671-3	7.5	23
2	Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. <i>BJU International</i> , 2009 , 103, 747-52	5.6	79
1	K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. <i>Methods in Enzymology</i> , 2008 , 439, 73-85	1.7	26